Trade Neurocrine Biosciences, Inc. - NBIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.53 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 106.36 |
| Open | 107.25 |
| 1-Year Change | -21.04% |
| Day's Range | 104.67 - 107.31 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 28, 2025 | 106.35 | 0.81 | 0.77% | 105.54 | 107.82 | 104.65 |
| Apr 25, 2025 | 106.36 | 1.18 | 1.12% | 105.18 | 107.33 | 103.74 |
| Apr 24, 2025 | 105.24 | 3.01 | 2.94% | 102.23 | 105.74 | 100.72 |
| Apr 23, 2025 | 102.82 | -1.05 | -1.01% | 103.87 | 105.90 | 102.28 |
| Apr 22, 2025 | 101.68 | 1.05 | 1.04% | 100.63 | 102.56 | 100.53 |
| Apr 21, 2025 | 100.61 | 1.03 | 1.03% | 99.58 | 101.82 | 97.79 |
| Apr 17, 2025 | 101.32 | 3.11 | 3.17% | 98.21 | 101.88 | 98.21 |
| Apr 16, 2025 | 100.03 | 3.16 | 3.26% | 96.87 | 100.52 | 96.57 |
| Apr 15, 2025 | 96.12 | -0.28 | -0.29% | 96.40 | 98.47 | 93.94 |
| Apr 14, 2025 | 94.76 | 1.72 | 1.85% | 93.04 | 95.51 | 91.96 |
| Apr 11, 2025 | 90.73 | 0.28 | 0.31% | 90.45 | 91.12 | 88.07 |
| Apr 10, 2025 | 90.57 | -2.11 | -2.28% | 92.68 | 94.09 | 86.71 |
| Apr 9, 2025 | 95.25 | 9.60 | 11.21% | 85.65 | 95.42 | 83.98 |
| Apr 8, 2025 | 87.15 | -6.37 | -6.81% | 93.52 | 94.20 | 86.20 |
| Apr 7, 2025 | 92.14 | 0.01 | 0.01% | 92.13 | 95.49 | 89.69 |
| Apr 4, 2025 | 95.60 | -3.21 | -3.25% | 98.81 | 98.81 | 93.41 |
| Apr 3, 2025 | 102.83 | -3.27 | -3.08% | 106.10 | 106.67 | 102.22 |
| Apr 2, 2025 | 107.85 | 2.96 | 2.82% | 104.89 | 108.38 | 104.89 |
| Apr 1, 2025 | 106.93 | -2.97 | -2.70% | 109.90 | 110.54 | 106.36 |
| Mar 31, 2025 | 110.37 | 0.12 | 0.11% | 110.25 | 112.16 | 109.29 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Neurocrine Company profile
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.
| Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com